Analyst Ratings For Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Today, Mizuho reiterated its Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI).
There are 10 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.
The current consensus rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) is Buy with a consensus target price of $79.20 per share, a potential 89.47% upside.
Some recent analyst ratings include
- 2/8/2019-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Mizuho
- 12/3/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) has coverage initiated with a Buy rating and $64.00 price target
- 11/12/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) has coverage initiated with a Outperform ➝ Reduce rating and $64.00 price target
- 10/2/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Cantor Fitzgerald with a $86.00 price target
- On 2/1/2019 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $46.17 per share and the total transaction amounting to $507,870.00.
- On 1/2/2019 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $35.21 per share and the total transaction amounting to $387,310.00.
- On 12/3/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $39.81 per share and the total transaction amounting to $437,910.00.
- On 11/16/2018 Gerald D Cagle, Director, bought 2,000 with an average share price of $41.75 per share and the total transaction amounting to $83,500.00.
- On 11/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $53.87 per share and the total transaction amounting to $592,570.00.
- On 10/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $60.56 per share and the total transaction amounting to $666,160.00.
- On 9/27/2018 Richard J Rubino, CFO, sold 66,605 with an average share price of $60.23 per share and the total transaction amounting to $4,011,619.15.
About Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.
Recent Trading Activity for Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Shares of Aerie Pharmaceuticals Inc closed the previous trading session at 41,34 −1,74 4,03 % with 41.31 shares trading hands.